Art

J-GLOBAL ID：201802272201719881   Reference number：18A1115313

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

癌治療のための抗HER2モノクローナル抗体および二重特異抗体の開発と臨床応用【JST・京大機械翻訳】

Author (7)： Yu Shengnan (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Liu Qian (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Han Xinwei (Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China) ,  Qin Shuang (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Zhao Weiheng (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) ,  Li Anping (Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China) ,  Wu Kongming (Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
Material： Experimental Hematology & Oncology (Web)
Volume： 6  Issue： 1  Page： 31  Publication year： 2017 
JST Material Number： U7482A  ISSN： 2162-3619  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： HER2-targeted immunotherapy co...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1115313&from=J-GLOBAL&jstjournalNo=U7482A") }}

Thesaurus term： tumor cell ,  clinical trial ,  patient ,  immunotherapy ,  *monoclonal antibody ,  interaction ,  alicyclic compound ,  fatty acid ,  aromatic carboxylic acid ,  oxygen heterocyclic compound ,  olefin compound ,  bridged compound ,  carboxylate(ester) ,  aminoalcohol ,  aminocarboxylic acid ,  secondary alcohol ,  hydroxy acid ,  hydroxy ketone ,  polyol
Semi thesaurus term： 抗HER2抗体 ,  進行乳癌 ,  転移性乳癌 ,  ペルツズマブ ,  トラスツズマブ ,  *特異抗体 ,  *erbB-2受容体 ,  癌治療 , 【Automatic Indexing@JST】

Author keywords (8)： HER2 ,  Trastuzumab ,  Pertuzumab ,  T-DM1 ,  Bispecific antibody ,  Ertumaxomab ,  MM-111 ,  HER2Bi-aATCs

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Paclitaxel

Reference (122)：

• Nature; Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab; HS Cho, K Mason, KX Ramyar, AM Stanley, SB Gabelli, DW Denney; 421; 6924; 2003; 756-760; 10.1038/nature01392; citation_id=CR1
• Eur J Pharm Sci; HER2-targeted antibody drug conjugates for ovarian cancer therapy; J Jiang, L Dong, L Wang, L Wang, J Zhang, F Chen; 93; 2016; 274-286; 10.1016/j.ejps.2016.08.015; citation_id=CR2
• Cancer Treat Rev; HER2 aberrations in cancer: implications for therapy; M Yan, BA Parker, R Schwab, R Kurzrock; 40; 6; 2014; 770-780; 10.1016/j.ctrv.2014.02.008; citation_id=CR3
• Clin Breast Cancer; HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues; MA Owens, BC Horten, MM Silva; 5; 1; 2004; 63-69; 10.3816/CBC.2004.n.011; citation_id=CR4
• Lancet; Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial; YJ Bang, E Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki; 376; 9742; 2010; 687-697; 10.1016/S0140-6736(10)61121-X; citation_id=CR5

Terms in the title (7)： 癌治療 ,  HER2 ,  モノクローナル抗体 ,  特異抗体 ,  開発 ,  臨床 ,  応用